Skip to main content

Table 3 Utilisation of antimalarial drugs across demographic categories

From: Adherence to treatment guidelines for uncomplicated malaria at two public health facilities in Nigeria; Implications for the ‘test and treat’ policy of malaria case management

 

Gender

Age category (years)

Antimalarial drugs

Female n (%)

Male n (%)

Under 5 n (%)

5 – 12 n (%)

13 – 18 n (%)

19 and above n (%)

Artemisinin-based combination therapy (ACT)

1127 (93)

881(94)

182(85)

45 (87)

101(97)

1286 (95)

  Artemether-lumefantrin (AL)

568 (50)

446 (51)

128 (70)

31 (69)

50 (50)

624 (49)

  Artesunate-amodiaquine (ASAQ)

113 (10)

125 (14)

29 (16)

3 (7)

15 (15)

184 (14)

  Artesunate-mefloquine (ASMF)

168 (15)

64 (7)

-

-

5 (5)

113 (9)

  Artesunate-sulphadoxine + pyrimethamine (ASSP)

115 (10)

72 (8)

18 (10)

11 (24)

9 (9)

82 (6)

  Dihydroartemisinin-piperaquine (DHAPQ)

163 (14)

174 (20)

7 (4)

-

22 (22)

283 (22)

Monotherapy

80(7)

61(6)

32(15)

7 (13)

3 (3)

70 (5)

  Sulphadoxine + pyrimethamine (SP)

39 (49)

28 (44)

4 (13)

2 (29)

2 (67)

44 (63)

  Artesunate (AS)

23 (29)

17 (27)

11 (34)

1 (14)

1 (33)

19 (27)

  Amodiaquine (AQ)

7 (9)

6 (9)

12 (38)

1 (14)

-

-

  Quinine (QN)

2 (3)

4 (6)

-

1(14)

-

5 (7)

  Proguanil (PG)

9(11)

6(14)

5 (16)

2 (29)

-

2 (3)

Co-medication

      

  Analgesics

920 (76)

783 (83)

119 (59)

34 (54)

87 (84)

1148 (85)

  Vitamin preparations

701 (56)

646 (69)

106 (52)

35 (56)

69 (66)

951 (70)

  Antibiotics

569 (47)

502 (53)

115 (57)

23 (37)

59 (57)

720 (53)

  1. NAUMC = Nnamdi Azikiwe University Medical Center, NAUTH = Nnamdi Azikiwe University Teaching Hospital.